L41,42 Background/Pathology IHD

Description

PHCY310 Quiz on L41,42 Background/Pathology IHD, created by Mer Scott on 19/05/2019.
Mer Scott
Quiz by Mer Scott, updated more than 1 year ago
Mer Scott
Created by Mer Scott over 5 years ago
13
0

Resource summary

Question 1

Question
Ischaemic heart disease (IHD) is the same thing as coronary artery disease (CAD) and coronary heart disease (CHD).
Answer
  • True
  • False

Question 2

Question
Atherosclerosis, a [blank_start]lipid[blank_end] deposition in the subendothelial space, causes IHD. There is endothelial dysfunction with [blank_start]decreased[blank_end] production of NO, less [blank_start]vasodilation[blank_end], increased risk of platelet [blank_start]adhesion[blank_end]. An influx of lipid scavenger cells ([blank_start]macrophages[blank_end]) cause inflammation, calcification and [blank_start]narrowing[blank_end] of the blood vessel by increasing plaque formation.
Answer
  • lipid
  • decreased
  • vasodilation
  • adhesion
  • macrophages
  • narrowing

Question 3

Question
Atherosclerotic plaque rupture causes a release of [blank_start]tissue[blank_end] factor (TF) and von Willebrand factor (vWF) vWF. More [blank_start]platelets[blank_end] adhere, activate, and aggregate. The coagulation cascade activates resulting in [blank_start]fibrinogen[blank_end] binding platelets to one another causing clot ([blank_start]thrombus[blank_end]) formation.
Answer
  • tissue
  • platelets
  • fibrinogen
  • thrombus

Question 4

Question
Which of these is not a risk factor for IHD?
Answer
  • Diabetes
  • Obesity
  • Smoking
  • Being a woman over 45
  • Alcohol overconsumption
  • Being a man over 45

Question 5

Question
Choose the incorrect statement.
Answer
  • Stable angina is a chronic form of IHD.
  • Unstable angina is an acute coronary syndrome.
  • Acute coronary syndromes are forms of IHD.
  • A STEMI is an acute coronoary syndrome while and NSTEMI is a chronic form of IHD.

Question 6

Question
Chronic stable angina is the initial manifestation of IHD in about 50% of patients. It is often caused by obstructive [blank_start]atherosclerotic[blank_end] lesions in the coronary arteries. Vasospasm at the site of an atherosclerotic plaque may further [blank_start]constrict[blank_end] blood flow and contribute to angina. Stable angina is characterised by a plaque with a thick fibrous cap and relatively [blank_start]small[blank_end] lipid core. Patients are generally in no acute distress and describe stable angina pain as a sensation of pressure, heaviness, tightness, or squeezing in the anterior [blank_start]chest[blank_end] area. Pain may radiate to the neck, jaw, shoulder, back, or arm and may be accompanied by dyspnoea, nausea, vomiting, or diaphoresis. Pain lasts a few [blank_start]minutes[blank_end] and is often provoked by [blank_start]exertion[blank_end] (e.g. walking, climbing stairs, gardening) or emotional stress; and relieved within minutes by [blank_start]rest[blank_end] or with sublingual nitroglycerin.
Answer
  • atherosclerotic
  • constrict
  • small
  • chest
  • minutes
  • exertion
  • rest

Question 7

Question
Acute coronary syndrome is the first sign of IHD in about 50% of patients.
Answer
  • True
  • False

Question 8

Question
Principles of treatment: 1. Angina: Increase myocardial O2 supply (by [blank_start]dilating[blank_end] the cardiac vasculature) and decrease O2 demand (by decreasing heart [blank_start]rate[blank_end], myocardial [blank_start]contractility[blank_end], and afterload) 2. ACS: Re-vascularisation/re-perfusion with mechanical or chemical Tx. - Mechanical: Percutaneous coronary intervention ([blank_start]PCI[blank_end]) = Angiography or [blank_start]angioplasty[blank_end] (using a balloon or a stent), or Coronary artery bypass graft (CABG) - Chemical: Anti-platelets or Anti-coagulants or Fibrinolytics
Answer
  • dilating
  • rate
  • contractility
  • PCI
  • angioplasty

Question 9

Question
Match the drug treatment to the purpose for IHD. - Dilate blood vessels and reduce cardiac load: [blank_start]nitrates, CCBs, ACEIs/ARBs, B-blockers[blank_end] - Stabilise atherosclerotic plaques: [blank_start]statins and other lipid-lowering meds[blank_end] - Prevent platelet aggregation: [blank_start]anti-platelets[blank_end] - Prevent propagation of thrombus: [blank_start]anti-coagulants[blank_end] - Break down thrombus: [blank_start]fibrinolytics[blank_end] - Pain relief: [blank_start]morphine[blank_end]
Answer
  • nitrates, CCBs, ACEIs/ARBs, B-blockers
  • statins and other lipid-lowering meds
  • anti-platelets
  • anti-coagulants
  • fibrinolytics
  • morphine

Question 10

Question
Nitrates are [blank_start]prodrugs[blank_end] that donate nitric oxide, NO. NO increases intracellular [blank_start]cGMP[blank_end], which relaxes [blank_start]smooth[blank_end] muscle cells and causes vasodilation. Frequent or high doses are associated with [blank_start]tolerance[blank_end].
Answer
  • prodrugs
  • cGMP
  • smooth
  • tolerance

Question 11

Question
Which of these is not a side effect of nitrates?
Answer
  • Hypotension
  • Flushing
  • Headache
  • Dizziness
  • Hypertension

Question 12

Question
Common DHP CCBs are [blank_start]amlodipine and felodipine[blank_end]. Non-DHP CCBS are [blank_start]verapamil and diltiazem[blank_end]. [blank_start]CCBs[blank_end] can cause headache, flushing, dizziness/postural hypotension, peripheral oedema, and constipation. [blank_start]Non-DHP CCBs[blank_end] can cause bradycardia (caution if patient is on a beta blocker).
Answer
  • amlodipine and felodipine
  • verapamil and diltiazem
  • CCBs
  • Non-DHP CCBs

Question 13

Question
ACE inhibitors can cause cough due to the build up of bradykinin (which is broken down by ACE).
Answer
  • True
  • False

Question 14

Question
If we give a β-blocker then we anticipate an increase in HR, and bronchial relaxation.
Answer
  • True
  • False

Question 15

Question
Anti-platelets: 1. Aspirin: Inhibits [blank_start]COX-1[blank_end] which decreases [blank_start]TxA2[blank_end] meaning less activation and aggregation. 2. Thienopyridines (e.g. [blank_start]clopidogrel, ticagrelor[blank_end]): Inhibits [blank_start]ADP[blank_end] receptor P2Y12 to decrease [blank_start]activation[blank_end] 3. GPIIb/IIIa inhibitors (e.g. [blank_start]abciximab, tirofiban[blank_end]): Inhibit [blank_start]GPIIb/IIIa[blank_end] receptor to decrease [blank_start]aggregation[blank_end]
Answer
  • COX-1
  • TxA2
  • clopidogrel, ticagrelor
  • ADP
  • activation
  • abciximab, tirofiban
  • aggregation
  • GPIIb/IIIa

Question 16

Question
Anti-coagulants inhibit formation and propagation of thrombi in arteries and veins. In ACS mainly the heparins are used. 1. Unfractionated heparin (UFH) increases the [blank_start]inhibitory[blank_end] action of anti-thrombin (AT) on factors [blank_start]Xa and IIa[blank_end] (and to some extent XIIa, XIa, and IXa). 2. Low molecular weight heparins (LMWHs) increase the inhibitor action of AT on factor [blank_start]Xa >> IIa[blank_end]. LMWH (e.g. enoxaparin) have a [blank_start]smaller[blank_end] molecular weight than UFH, a longer [blank_start]half-life[blank_end], and can be administered [blank_start]subcutaneously[blank_end] (self-administered).
Answer
  • inhibitory
  • Xa and IIa
  • Xa >> IIa
  • smaller
  • half-life
  • subcutaneously

Question 17

Question
Fibrinolytics break down fibrin stabilised clots. They are used more in pulmonary [blank_start]embolism[blank_end] or stroke than in IHD. Examples are [blank_start]alteplase and reteplase[blank_end], synthetic tissue plasminogen activators ([blank_start]tPAs[blank_end]).
Answer
  • embolism
  • alteplase and reteplase
  • tPAs
Show full summary Hide full summary

Similar

Product Design
cmbj
Government of India Act 1935
jacksearle
AQA GCSE Biology genetic variation
Olivia Phillips
Fundamentals in Chemistry
kate.siena
OCR Gateway GCSE - Biology B1
joshua6729
World Cup Quiz
Alex Declan
GCSE AQA Chemistry Atomic Structure and Bonding
Joseph Tedds
Master French
jedimaster3721
Unit 3 Business Studies
Lauren Thrower
PMP Formulas
Krunk!
PHR Sample Questions
Elizabeth Rogers8284